CTOs on the Move

Bristol-Myers Squibb

www.bms.com

 
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious and life-threatening diseases. Our medicines are helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience, fibrosis and others. Through the Bristol-Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world`s most vulnerable people. Each day, our employees around the world work together for patients – it drives everything we do.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.bms.com
  • 345 Park Avenue
    New York, NY USA 10154
  • Phone: 212.546.4000

Executives

Name Title Contact Details
Staci Hargraves
SVP, Head of Transformation, Drug Development Profile
Ami Mehta
Associate Director, IT Lead for Cell Therapy Medical Affairs/Ex US Commercial Profile
Rosimar Lehr
Associate Director, Contract Lead, IT Services, Agile Sourcing Profile
Michael Morris
Executive Director, Global Procurement IT Profile
Ari Hamalian
Executive Director IT Risk Operations and Supplier Resilience Profile

Jobs

Head of Global Talent Acquisition

Bristol-Myers Squibb Princeton, NJ
Job Description

The Head Global Talent Acquisition will report to the Head of Global Talent and Organizational Effectiveness who reports to the company’s Chief Human Resources Officer. The incumbent will lead a global team of 30+ BMS individuals and 110+ recruitment professionals working for Cielo (US) and Alexander Mann ...

Funding

Bristol-Myers Squibb raised $20.2M on 12/17/2020

Similar Companies

CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in a Phase 3 clinical trial enrolling patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows for five additional years of QIDP market exclusivity in the event of U.S. approval. It is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes and topical hydrogels. The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.

Good Therapeutics

Good Therapeutics is an early-stage biotechnology company based in Seattle, Washington. We are developing "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity. Our goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy.

jCyte

jCyte is a clinical-stage company focused on the application of progenitor cell-based technology in retinal diseases. The Company`s allogeneic product candidate, jCell, is delivered by simple intravitreal injection without the need for surgery or immune suppression. jCyte has completed a phase 1/2a, phase 1/2a extension and phase 2b clinical trials testing jCell in patients with Retinitis Pigmentosa.

Exalenz Bioscience

Exalenz Bioscience is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Glympse Bio

Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases.